<![CDATA[Technology Reports]]> http://www.cadth.ca/xml.php/en/products/health-technology-assessment Wed, 01 Apr 2015 06:51:03 -0400 Zend_Feed http://blogs.law.harvard.edu/tech/rss <![CDATA[Physical Interventions to Interrupt or Reduce the Spread of Respiratory Viruses — Resource Use Implications: A Systematic Review]]> Thu, 22 Dec 2011 10:50:55 -0500 <![CDATA[Robot-assisted Surgery versus Open Surgery and Laparoscopic Surgery: Clinical Effectiveness and Economic Analyses]]> Report Summary
A few Canadian hospitals have developed surgical robotics programs using technology such as the Da Vinci® Surgical System, to help surgeons perform surgery. This technology is however associated with significant capital and operating costs. Given the relatively recent introduction of surgical robotic systems for certain programs of care (prostatectomy, hysterectomy, nephrectomy and cardiac [coronary artery bypass graft and mitral valve repair] procedures), as well as costs related to the acquisition and operation of this technology, an assessment of the clinical, economic, and potential health services impact of surgical robotic systems is needed to inform rational funding decisions in Canada.

Summaries: Project in Brief

Report: Technology Report

]]> Report Summary
A few Canadian hospitals have developed surgical robotics programs using technology such as the Da Vinci® Surgical System, to help surgeons perform surgery. This technology is however associated with significant capital and operating costs. Given the relatively recent introduction of surgical robotic systems for certain programs of care (prostatectomy, hysterectomy, nephrectomy and cardiac [coronary artery bypass graft and mitral valve repair] procedures), as well as costs related to the acquisition and operation of this technology, an assessment of the clinical, economic, and potential health services impact of surgical robotic systems is needed to inform rational funding decisions in Canada.

Summaries: Project in Brief

Report: Technology Report

]]> Tue, 20 Mar 2012 15:42:00 -0400 <![CDATA[Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses]]> This report focuses on first-line treatment using vancomycin or metronidazole for initial or recurrent moderate to severe Clostridium difficile infection.  Clinical, economic, and health services impact considerations are evaluated.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> This report focuses on first-line treatment using vancomycin or metronidazole for initial or recurrent moderate to severe Clostridium difficile infection.  Clinical, economic, and health services impact considerations are evaluated.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> Wed, 26 Jan 2011 14:43:46 -0500 <![CDATA[Clopidogrel versus Other Antiplatelet Agents: A CADTH Technology Assessment Report Series]]> This series of three health technology assessments examines the clinical and cost-effectiveness of Clopidogrel (alone or in combination with acetylsalicylic acid i.e., ASA) versus other antiplatelet agents (ASA, ticlopidine, dipyridamole, extended-release dipyridamole 200 mg/ASA 25 mg combination) for secondary prevention of different vascular event indications. 

  • Comparisons include monotherapy and dual combination therapy regimens.  Assessments include an analysis of current clinical practice guidelines.
  • Each technology assessment report has been extensively peer-reviewed by external clinical and methodological experts.

Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses

(H1481 Released November 2010)

Report

Summary 

Clopidogrel Compared With Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults Undergoing Percutaneous Coronary Intervention: Clinical and Cost-Effectiveness Analyses

(H2481 Released November 2010)

Report

Summary

Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses

(H0481 Released December 2009)

Report

Summaries 

]]> This series of three health technology assessments examines the clinical and cost-effectiveness of Clopidogrel (alone or in combination with acetylsalicylic acid i.e., ASA) versus other antiplatelet agents (ASA, ticlopidine, dipyridamole, extended-release dipyridamole 200 mg/ASA 25 mg combination) for secondary prevention of different vascular event indications. 

  • Comparisons include monotherapy and dual combination therapy regimens.  Assessments include an analysis of current clinical practice guidelines.
  • Each technology assessment report has been extensively peer-reviewed by external clinical and methodological experts.

Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses

(H1481 Released November 2010)

Report

Summary 

Clopidogrel Compared With Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults Undergoing Percutaneous Coronary Intervention: Clinical and Cost-Effectiveness Analyses

(H2481 Released November 2010)

Report

Summary

Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses

(H0481 Released December 2009)

Report

Summaries 

]]> Tue, 30 Nov 2010 11:24:10 -0500 <![CDATA[Non-Emergency Telecardiology Consultation Services: Rapid Review of Clinical and Cost Outcomes]]> Mon, 29 Nov 2010 14:27:24 -0500 <![CDATA[Teledermatology Services: Rapid Review of Diagnostic, Clinical Management and Economic Outcomes]]> Mon, 29 Nov 2010 14:28:36 -0500 <![CDATA[Pharmacologic-based Strategies for Smoking Cessation]]> Smoking is one of the major risk factors for cancer, respiratory disease, and cardiovascular disease. Smoking tobacco is a risk factor that can be changed — by quitting permanently. Unfortunately, quitting smoking is much easier said than done. So how can we best help smokers to quit? Which of the smoking cessation aids works best? Which of these options offers the best value to Canadians and our health care system?

To address these questions, CADTH:

  • Compared drug-based smoking cessation aids to determine which of these works best (clinical effectiveness) at six months and 12 months after attempting to quit smoking
  • Performed an economic analysis to determine which smoking cessation therapy was the most cost-effective for patients, drug plans, and the Canadian health care system.

Summaries:

Report:

First Nations and Inuit Tools

National Association of Friendship Centres

Assembly of First Nations

Government of Nunavut

The materials have been developed in partnership with the Assembly of First Nations, the National Association of Friendship Centres, Government of Nunavut and Health Canada.  Versions suitable for professional printing are available, please contact your jurisdictional Liaison Officer.

]]> Smoking is one of the major risk factors for cancer, respiratory disease, and cardiovascular disease. Smoking tobacco is a risk factor that can be changed — by quitting permanently. Unfortunately, quitting smoking is much easier said than done. So how can we best help smokers to quit? Which of the smoking cessation aids works best? Which of these options offers the best value to Canadians and our health care system?

To address these questions, CADTH:

  • Compared drug-based smoking cessation aids to determine which of these works best (clinical effectiveness) at six months and 12 months after attempting to quit smoking
  • Performed an economic analysis to determine which smoking cessation therapy was the most cost-effective for patients, drug plans, and the Canadian health care system.

Summaries:

Report:

First Nations and Inuit Tools

National Association of Friendship Centres

Assembly of First Nations

Government of Nunavut

The materials have been developed in partnership with the Assembly of First Nations, the National Association of Friendship Centres, Government of Nunavut and Health Canada.  Versions suitable for professional printing are available, please contact your jurisdictional Liaison Officer.

]]> Wed, 27 Feb 2013 08:26:07 -0500 <![CDATA[Bariatric Surgery for Severe Obesity: Systematic Review and Economic Evaluation]]> The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review and primary economic evaluation to assess the clinical effectiveness, cost-effectiveness, and health services impact of bariatric surgery procedures for the management of severe obesity.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review and primary economic evaluation to assess the clinical effectiveness, cost-effectiveness, and health services impact of bariatric surgery procedures for the management of severe obesity.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> Wed, 29 Sep 2010 12:06:11 -0400 <![CDATA[Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses]]> Atrial fibrillation (AF) is a type of heart rhythm disturbance or arrhythmia that affects over 200,000 Canadians, including more than 5% of the population over the age of 65. The most common type of arrhythmia, AF is associated with a high degree of morbidity and mortality, including an increased risk of stroke.

 

First-line therapy for AF is antiarrhythmic drugs (AADs), which are used to either terminate the arrhythmia or control symptoms. While drug treatment has the advantage of being non-invasive, chronic administration may be required. On the other hand, minimally invasive ablation procedures – a relatively new, non-surgical procedure that uses energy directed through a catheter to destroy tiny sections of malfunctioning heart tissue to restore normal heart rhythm – may obviate the need for long-term use of AADs. Despite its potential benefits, there is uncertainty regarding the effectiveness of this technology and which patients are most likely to benefit from it.

This health technology assessment is aimed at evaluating the clinical and cost-effectiveness of minimally invasive ablation procedures for terminating arrhythmia in adults with AF. The report may be of interest to health researchers and professionals (particularly specialists) working in cardiology, as well as those working within a health ministry, health region, or hospital.

 

Report

Summaries

 

]]> Atrial fibrillation (AF) is a type of heart rhythm disturbance or arrhythmia that affects over 200,000 Canadians, including more than 5% of the population over the age of 65. The most common type of arrhythmia, AF is associated with a high degree of morbidity and mortality, including an increased risk of stroke.

 

First-line therapy for AF is antiarrhythmic drugs (AADs), which are used to either terminate the arrhythmia or control symptoms. While drug treatment has the advantage of being non-invasive, chronic administration may be required. On the other hand, minimally invasive ablation procedures – a relatively new, non-surgical procedure that uses energy directed through a catheter to destroy tiny sections of malfunctioning heart tissue to restore normal heart rhythm – may obviate the need for long-term use of AADs. Despite its potential benefits, there is uncertainty regarding the effectiveness of this technology and which patients are most likely to benefit from it.

This health technology assessment is aimed at evaluating the clinical and cost-effectiveness of minimally invasive ablation procedures for terminating arrhythmia in adults with AF. The report may be of interest to health researchers and professionals (particularly specialists) working in cardiology, as well as those working within a health ministry, health region, or hospital.

 

Report

Summaries

 

]]> Thu, 30 Sep 2010 11:23:38 -0400 <![CDATA[Policy Guidance on Hip Protectors in Long-Term Care]]> http://www.cadth.ca/media/pdf/CADTH_Hip_Protectors_Policy_Guidance_e.pdf Tue, 24 May 2011 13:11:41 -0400 <![CDATA[Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease]]> The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review and primary economic evaluation to evaluate the clinical effectiveness, cost-effectiveness, and health services impact of triple therapy in the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) compared with dual bronchodilator therapy, combination therapy, and monotherapy.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review and primary economic evaluation to evaluate the clinical effectiveness, cost-effectiveness, and health services impact of triple therapy in the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) compared with dual bronchodilator therapy, combination therapy, and monotherapy.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> Wed, 12 May 2010 13:42:58 -0400 <![CDATA[Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease]]> The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review to evaluate the clinical, economic and budgetary implications of pulmonary rehabilitation (PR) programs to assist policy-makers and health care providers with future decisions in the establishment and utilization of these programs.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review to evaluate the clinical, economic and budgetary implications of pulmonary rehabilitation (PR) programs to assist policy-makers and health care providers with future decisions in the establishment and utilization of these programs.

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> Mon, 17 May 2010 09:12:30 -0400 <![CDATA[Polymerase Chain Reaction Tests for Methicillin-Resistant Staphylococcus aureus in Hospitalized Patients: Clinical Effectiveness Analysis.]]> Fri, 11 Jan 2013 10:56:23 -0500 <![CDATA[Recombinant Activated Factor VII for Prevention of Bleeding Unrelated to Hemophilia: Clinical and Economic Systematic Review]]> CADTH’s health technology assessment report examines the clinical efficacy and cost-effectiveness of off-label use of recombinant activated factor VII (rFVIIa), an agent currently approved to control bleeding in patients with either hemophilia A or B and clotting factor inhibitors.  

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> CADTH’s health technology assessment report examines the clinical efficacy and cost-effectiveness of off-label use of recombinant activated factor VII (rFVIIa), an agent currently approved to control bleeding in patients with either hemophilia A or B and clotting factor inhibitors.  

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> Mon, 08 Feb 2010 13:50:45 -0500 <![CDATA[Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses]]> http://www.cadth.ca/en/publication/2708 CADTH’s health technology assessment report on clopidogrel versus other antiplatelet agents examines the clinical efficacy and cost-effectiveness of this treatment strategy for secondary prevention of vascular events in adults with cerebrovascular disease. The report also assesses current clinical practice guidelines and the health services impact of different antiplatelet therapies.

Report

This complete report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> CADTH’s health technology assessment report on clopidogrel versus other antiplatelet agents examines the clinical efficacy and cost-effectiveness of this treatment strategy for secondary prevention of vascular events in adults with cerebrovascular disease. The report also assesses current clinical practice guidelines and the health services impact of different antiplatelet therapies.

Report

This complete report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries

]]> Mon, 29 Nov 2010 11:22:55 -0500